Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 4/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 2/20 | 0.50 |
| ▸ | IKBKB | O14920 | 2/20 | 0.48 |
| ▸ | CHUK | O15111 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5204218 | 0.84 | HRH1 (0.79) | HRH1SLC6A2SLC6A3SLC6A4IKBKB | |
| SCHEMBL211130 | 0.84 | HRH1 (1.00) | HRH1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL21468838 | 0.84 | HRH1 (1.00) | HRH1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL14834207 | 0.83 | SLC6A2 (0.70) | HRH1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL2300957 | 0.83 | SLC6A4 (0.53) | HRH1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL12420545 | 0.82 | HRH1 (0.51) | HRH1SLC6A2SLC6A3SLC6A4IKBKB | |
| Hydrochloric Acid SCHEMBL4443248 | 0.82 | HRH1 (0.96) | HRH1SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL1237796 | 0.82 | HRH1 (0.96) | HRH1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL13703555 | 0.80 | HRH1 (0.71) | HRH1SLC6A2SLC6A3SLC6A4IKBKB | |
| SCHEMBL12735827 | 0.80 | OPRK1 (0.53) | HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | HRH1 75/4885SLC6A2 752/4885SLC6A3 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.